Lung Cancer Survival Rate

Lung cancer survival rate describes how many patients are alive after a certain amount of time since being diagnosed. The general 5-year lung cancer survival rate is 18.6%, according to the American Lung Association (ALA). That said, it may be possible to outlive the average lung cancer survival rate with medical care. Learn more now.

Free Case Review

What Is the Survival Rate of Lung Cancer?

Doctors will provide you with survival rate data after confirming you have lung cancer through diagnostic tests. Lung cancer has one of the lowest long-term survival rates, according to the ALA.

The overall 5-year lung cancer survival rate is 18.6%, meaning less than 1 in 5 patients are still alive 5 years after being diagnosed.

That said, lung cancer survival rates can vary depending on the cancer stage, type, and individual patient health factors.

Further, lung cancer survival rate statistics are estimates based on available patient data. It may be possible for you to live for many years or decades following a lung cancer diagnosis.

The best chance you have at outliving the average lung cancer survival rate is to get treatment. Lung cancer treatments can be very expensive, but you can afford them with our team’s help. Learn more now with a free case review.

Get Help for Asbestos Lung Cancer
  • Access Financial Aid and Justice
  • Learn About Your Options
  • Contact Us for Free
Free Case ReviewAn older man and his wife hold each other.

Lung Cancer Survival Rate vs. Life Expectancy

Survival rates and life expectancies are two statistics doctors use to measure a lung cancer prognosis. However, the two terms are not the same.

Life expectancy is how long a doctor believes you’ll live given the type and stage of lung cancer you have. The overall life expectancy for lung cancer ranges from 7-16 months, but some patients can live for decades thanks to medical treatments.

Survival Rates by Lung Cancer Type

There are two main types of lung cancer, and each type has its own unique survival rate data available. View survival rates by type below.

Non-Small Cell Lung Cancer Survival Rates

Non-small cell lung cancer (NSCLC) is the most common lung cancer type, making up over 80% of all cases.

The overall 5-year survival rate for NSCLC is 26%, according to the American Cancer Society (ACS). Doctors can also diagnose cases of NSCLC into several subtypes, each of which has its own unique survival rate data.

Survival rates for NSCLC subtypes include:
  • Adenocarcinoma: This is the most common subtype, being found in 40% of NSCLC diagnoses. This subtype forms in the glands that line the lings. The overall 5-year survival rate for this subtype is 12%, as noted by the U.S. National Library of Medicine.
  • Large cell carcinoma: This is a catch-all subtype for cases that don’t easily fit into one of the other two subtypes. Only 7% of patients have this NSCLC subtype, and the 5-year survival rate is 19%, according to the journal Translational Lung Cancer Research.
  • Squamous cell carcinoma: This subtype accounts for up to 30% of NSCLC cases and forms in the cells lining the lungs. The 5-year survival rate is 24%, according to Harvard Health Publishing.

Small Cell Lung Cancer Survival Rate

Small cell lung cancer (SCLC) is a less common type of lung cancer that grows and spreads faster than compared to SCLC. It represents 10%-15% of lung cancer diagnoses.

Patients with SCLC have an overall 5-year survival rate of only 7%, as noted by the ACS.

Get help after your NSCLC or SCLC diagnosis: Call (877) 446-5767 to learn more.

Survival Rates by Lung Cancer Stage

Survival rates also vary depending on lung cancer stage. Cancer stage allows doctors to track how far the cancer has spread through the body. Lung cancer survival rates are higher if the cancer stage is lower.

Here’s a breakdown of lung cancer survival rates by stage.

Stage 1 Lung Cancer Survival Rate

In this stage, lung cancer has not yet spread outside the lung. Roswell Park Comprehensive Cancer Center notes the 5-year lung cancer survival rate for this stage ranges from 70%-90%.

Stage 1 lung cancer patients typically have the most treatment options available, meaning there’s a better chance they’ll be considered cured and become long-term survivors.

Stage 2 Lung Cancer Survival Rate

The 5-year lung cancer survival rate in this stage is 50%-60%, according to Roswell Park Comprehensive Cancer Center.

Stage 2 lung cancer has spread to lymph nodes inside the lung, or there is more than one tumor in the same lung lobe. That said, treatments are still often available to help patients live longer.

Stage 3 Lung Cancer Survival Rate

By stage 3, the cancer has spread to nearby lymph nodes, and there is more than one tumor in a different lung lobe. The cancer spread limits available treatment options and thus lowers the overall survival rate.

The 5-year survival rate for stage 3 lung cancer is 20%-40%, as noted by Roswell Park Comprehensive Cancer Center.

Stage 4 Lung Cancer Survival Rate

Stage 4 lung cancer is the most advanced and thus, the survival rates are the poorest. The cancer has spread to the opposite lung, the fluid around the lung, or distant organs like the brain.

The ACS notes that the 5-year survival rate for stage 4 lung cancer is between 3% and 9%.

Afford treatments that can improve your lung cancer survival rate. Get started with a free case review.

Get Help for Asbestos Lung Cancer
  • Access Financial Aid and Justice
  • Learn About Your Options
  • Contact Us for Free
Free Case ReviewAn older man and his wife hold each other.

Lung Cancer Survival Rate by Demographic

Besides the cancer stage and type, lung cancer survival rates may also vary depending on demographics like a patient’s sex, race, and age. See how below.

Sex of the Patient

Women have slightly higher lung cancer survival rates than men. The American Society of Clinical Oncology (ASCO) found that men have an overall 5-year lung cancer survival rate of 18%, while women have a 5-year survival rate of 25%.

Age of the Patient

Older lung cancer patients have lower survival rates, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.

Lung cancer patients under the age of 50 had a 5-year survival rate of 47.4%. By contrast, those aged 65 or older had a 5-year survival rate of 28.5%.

Race of the Patient

A 2018 study in the Journal of Thoracic Oncology revealed that race may also affect lung cancer survival rates. In the U.S., the national 5-year NSCLC survival rate is 15% among black people and 18% among white people.

Improving Lung Cancer Survival Rates With Treatment

Getting treatment gives patients the best chance of outliving the average lung cancer survival rate. This is especially true for those whose lung cancer is caught at an early stage.

Lung cancer treatments allow doctors to remove or destroy as much of the cancer as possible.

Lung cancer treatments that can influence survival include:

Chemotherapy

This treatment uses powerful chemicals to kill rapidly growing cells in your body, such as lung cancer cells.

Patients with metastatic NSCLC that received chemotherapy had a 5-year survival rate of 14% in a study from the Journal of Clinical Oncology.

Immunotherapy

Immunotherapy medications train the body so it can fight cancer.

The overall 5-year survival rate in metastatic NSCLC patients treated with the immunotherapy drugs Opdivo® and Yervoy® was 24%, according to the Journal of Clinical Oncology.

Radiation Therapy

Radiation therapy involves using types of radiation, such as X-rays, to kill cancerous cells. Different types of radiation can be used to help lung cancer patients.

Stage 1 NSCLC patients treated with stereotactic body radiation therapy (SBRT) have a 3-year survival rate ranging from 55% to 91%. Those treated with another type called radiofrequency ablation have a 3-year survival rate of 60% and a 5-year survival rate of 45%.

Surgery

Surgeons remove lung cancer tumors, along with the lung lobe or all of the lung that the cancer has grown into.

According to a 2021 Thoracic Oncology: Original Research study, the 5-year survival rate for lung cancer after surgery is around 65%.

Targeted Cell Therapy

This is a kind of cancer treatment that targets mutations and abnormalities in cancer cells that cause them to grow, divide, and spread uncontrollably.

The 1-, 3-, and 5-year survival rates for lung cancer patients treated with this therapy were 91.9%, 83.8%, and also 83.8%, respectively, in a 2021 study.

Learn how you can afford treatments to improve your lung cancer survival rate now: Call (877) 446-5767.

Find Help With Outliving Average Lung Cancer Survival Rates

Lung cancer is a devastating disease with low survival rates. Fortunately, you can increase your life expectancy by seeking treatment. Treatments can be expensive, but Lung Cancer Group is here to assist you.

Our team can help you file:

  • Lung cancer lawsuits: Through a lawsuit, you recover compensation from manufacturers who used asbestos in their products if you developed lung cancer due to asbestos exposure.
  • Asbestos trust fund claims: Trust funds can give those with asbestos-related lung cancer compensation for their medical bills and pain and suffering. Asbestos trust funds are legal entities organized through bankruptcy courts to pay negligent companies’ asbestos liability claims.
  • Veterans benefits claims: Veterans with lung cancer may qualify for disability and health care benefits.

Get a free case review to learn more.

Lung Cancer Survival Rate FAQs

What affects lung cancer survival rates?

Many factors affect lung cancer survival rates, including what type of this cancer you have, its stage, your age, and your overall health.

Arguably, the best way to improve your lung cancer survival rate is to get treated. Without treatment, lung cancer can be deadly in months.

No. While there’s not a universal cure for lung cancer, those diagnosed and treated in the early stages may be considered cured. These patients outlive typical lung cancer survival rates by years and decades.

Further, treatments like surgery and chemotherapy can possibly prolong your lifespan even if your cancer is not considered curable.

Yes, in some cases. Lung cancer is more likely to go into remission — where there are no signs of the cancer — if you undergo multiple treatments and you were diagnosed and treated early.

Late-stage (metastatic) cancer that has spread to distant organs is less likely to go into remission. An oncology (cancer) health care provider can tell you if it’s likely that your cancer will enter remission.

You can improve your lung cancer survival rate by accessing proven lung cancer treatment options like surgery and radiation therapy, seeking financial compensation, and finding resources for lung cancer support.

Lung Cancer Group was established by a team of caring advocates so those with lung cancer and other asbestos-related diseases can get the help they deserve. Our site provides the most accurate and up-to-date information about lung cancer, its link to asbestos, and financial compensation available to patients. Contact us to learn more and get assistance.

  1. American Association for Cancer Research Journals (2023 February 15). Clinical Cancer Research. “Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer.” Retrieved February 27, 2023 from https://aacrjournals.org/clincancerres/article/29/4/705/716469/Five-Year-Clinical-Outcomes-after-Neoadjuvant.

  2. American Cancer Society (2022 March 2). “Lung Cancer Survival Rates.” Retrieved February 27, 2023 from https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html.

  3. American Lung Association (2022 November 17). “Lung cancer fact sheet.” Retrieved February 27, 2023 from https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet.

  4. American Society of Clinical Oncology (2022 December). “Lung Cancer – Non-Small Cell: Statistics.” Retrieved February 27, 2023 from https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.

  5. Brahmer, J. et. al. (2022 October 12). “Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227.” Retrieved February 27, 2023 from https://ascopubs.org/doi/abs/10.1200/JCO.22.01503?role=tab.

  6. Cancer Research UK. “Lung cancer survival statistics.” Retrieved February 27, 2023 from https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival#collapseOne.

  7. Cancer Research UK (2022 December 21). “Survival for Lung Cancer.” Retrieved February 27, 2023 from https://www.cancerresearchuk.org/about-cancer/lung-cancer/survival.

  8. Centers for Disease Control and Prevention (2022 October 25). “What is Lung Cancer?” Retrieved February 27, 2023 from https://www.cdc.gov/cancer/lung/basic_info/what-is-lung-cancer.htm.

  9. CHEST Journal (2021 May). Thoracic Oncology: Original Research. “Sex and Survival After Surgery for Lung Cancer.” Retrieved February 27, 2023 from https://journal.chestnet.org/article/S0012-3692(20)35155-2/fulltext.

  10. Cleveland Clinic (2022 October 31). “Lung Cancer.” Retrieved February 27, 2023 from https://my.clevelandclinic.org/health/diseases/4375-lung-cancer.

  11. Harvard Health Publishing (2020 September 30). “Squamous Cell Carcinoma of the Lung.” Retrieved February 27, 2023 from https://www.health.harvard.edu/cancer/squamous-cell-carcinoma-of-the-lung.

  12. National Cancer Institute (2023 February 17). “Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version).” Retrieved February 27, 2023 from https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq.

  13. National Library of Medicine (2022 June 21). StatPearls. “Lung Adenocarcinoma.” Retrieved February 27, 2023 from https://www.ncbi.nlm.nih.gov/books/NBK519578/.

  14. National Library of Medicine (2022 July 19). StatPearls. “Radiation Therapy For Early Stage Non-Small Cell Lung Cancer.” Retrieved February 27, 2023 from https://www.ncbi.nlm.nih.gov/books/NBK459385/.

  15. National Library of Medicine (2021 August). Asian Pacific Journal of Cancer Prevention. “Lung Cancer Survival with Current Therapies and New Targeted Treatments: A Comprehensive Update from the Srinagarind Hospital-Based Cancer Registry from (2013 to 2017).” Retrieved February 27, 2023 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629471/.

  16. National Library of Medicine: PubMed Central (2018 June 6). Journal of Thoracic Oncology. “Racial disparities in lung cancer survival: The contribution of stage, treatment, and ancestry.” Retrieved February 27, 2023 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153049/.

  17. National Library of Medicine: PubMed Central (2016 January). Diagnostic and Interventional Radiology. “Radio frequency ablation for long tumors outcomes effects and survival and prognostic factors.” Retrieved February 27th 2023 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712901/.

  18. National Library of Medicine: PubMed Central (2013). Systematic Reviews. “Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis.” Retrieved February 27, 2023 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579762/.

  19. OncoLink (2013 June 24). “Chemotherapy in Early Stage Non Small Cell Lung Cancer.” Retrieved February 27, 2023 from https://www.oncolink.org/cancers/lung/non-small-cell-lung-cancer-nsclc/treatments/chemotherapy-in-early-stage-non-small-cell-lung-cancer.

  20. Roswell Park Comprehensive Cancer Center (2022 January 7). “Understanding Lung Cancer Survival Rate.” [Video File]. Retrieved February 27, 2023 from https://www.youtube.com/watch?v=qRPXDbi9E_E.

  21. Statistics Canada (2022 January 4). “Lung cancer is the leading cause of cancer death in Canada.” Retrieved February 27, 2023 from https://www.statcan.gc.ca/o1/en/plus/238-lung-cancer-leading-cause-cancer-death-canada.

  22. Tai, Q. et. al. (2020 March 30). “Clinical characteristics and treatments of large cell lung carcinoma: a retrospective study using SEER data.” Retrieved March 8, 2023 from https://tcr.amegroups.com/article/view/36810/html.

Free Case Review

Get Financial Compensation for Lung Cancer

  • Afford medical expenses and any other bills
  • Find peace of mind for you and your family
  • Get justice from the companies that harmed you

Call (877) 446-5767 or fill out the form to connect with our team and pursue financial compensation after a lung cancer diagnosis.

Start a Free Case Review

Secure Submission

Call us at (877) 446-5767 Talk to us via Live Chat